meetings

Transcript, Meeting 19, Session 6

SESSION 6: DELIBERATION AND BIOETHICS EDUCATION: CASE STUDY OF PUBLIC HEALTH EMERGENCY RESPONSE (CONTINUED)

DR. GUTMANN: Welcome back, everybody. We  are going to move on to our second speaker for Public  Health Emergency Response, Dr. Anthony Fauci.

Date

Thu, 11/06/2014

Transcript, Meeting 19, Opening Remarks and Session 5

SESSION 5: DELIBERATION AND BIOETHICS EDUCATION: CASE STUDY OF PUBLIC HEALTH EMERGENCY RESPONSE

       DR. GUTMANN: Good morning, everybody. I'm Amy Gutmann, President of the University of Pennsylvania and Chair of the Presidential Commission for the Study of Bioethical Issues.

Date

Thu, 11/06/2014

Transcript, Meeting 19, Session 3

SESSION 3: MEMBER DISCUSSION [CONSENT CAPACITY FRAMING AND POSSIBLE RECOMMENDATIONS]

Date

Wed, 11/05/2014

Transcript, Meeting 19, Session 7 and Closing Remarks

SESSION 7: DELIBERATION AND BIOETHICS EDUCATION: OVERVIEW

DR. WAGNER:  Folks, thank you for joining us.  This panel is going to be a little more theoretical, less focused on a particular incident, and a little less applied.  It will give us an overview of what deliberation of bioethics education can mean generally.  And folks, the way we will work this is I will introduce you each, one at a time, and ask you to speak.

Do they have a ten minute time limit, also?

DR. GUTMANN:  Yes.

Date

Thu, 11/06/2014

Transcript, Meeting 19, Opening Remarks and Session 1

DR. GUTMANN:  Welcome everybody.  I'm Amy Gutmann.  I'm President of the University of Pennsylvania.  And I'm Director and Chair of the Presidential Commission for the Study of Bioethical Issues.  And on behalf of myself and our Vice Chair, Jim Wagner, and all of our Commission members, I'd like to welcome you to this, our nineteenth meeting. I will begin by noting the presence of our designated federal official, Bioethics Commission Executive Director Lisa M. Lee.  Lisa, please stand up. Thank you.

Date

Wed, 11/05/2014

Transcript, Meeting 18, Session 5 and Closing Remarks

DR. GUTMANN: We are blessed to have a great group of people presenting with expertise that is wide ranging in neuroscience, research, the ethics of neuroscience research and the ethics of the potential applications of the results of this research. And this is a unique opportunity for us as a Commission to hear from you. So give us one recommendation that you would like to see us, what we do in our report, whether it be what you want to make sure we attend to, something you think is really important for us to observe in the report.

Date

Wed, 08/20/2014

Transcript, Meeting 18, Session 4

SESSION 4: NEUROSCIENCE RESEARCH AND DIMINISHED CAPACITY

DR. GUTMANN: Great, this panel is going to revisit a topic that we discussed in our last meeting as well, and that is capacity to consent in research. And first we will hear from Dr. Jerry Menikoff, who is the director of the Office of Human Research Protections in the U.S. Department of Health and Human Services.

Date

Wed, 08/20/2014

Transcript, Meeting 18, Session 3

SESSION 3: NEUROSCIENCE RESEARCH—CLINICAL INNOVATION AND APPLICATIONS

DR. WAGNER: Welcome back everybody. I hope you enjoyed a good break over lunch. We are going to turn our attention now to clinical innovation and applications through neuroscience research. We are going to hear first ‑‑ same process, panelists. We are going to hear from each of you in rapid and fire sequence, and then have an opportunity to engage you with our questions from the panel.

Date

Wed, 08/20/2014

Transcript, Meeting 18, Session 2

SESSION 2: DIRECT-TO-CONSUMER NEUROTECHNOLOGY

DR. WAGNER:  Let me welcome all of our Commissioners back.  And who are we waiting for?  Steve.

DR. GUTMANN:  Let's just get started.  We can get started.  People will come very quickly when you ‑‑ once you get started.

DR. WAGNER:  Steve and John are out in the hallway.  And ‑‑ are they just chatting?  Here comes John.

Date

Wed, 08/20/2014

Pages

Subscribe to RSS - meetings